Logo image of ALMS

ALUMIS INC (ALMS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALMS - US0223071020 - Common Stock

8.955 USD
-0.8 (-8.25%)
Last: 1/2/2026, 8:00:01 PM
8.93 USD
-0.03 (-0.28%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALMS. ALMS was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ALMS as it has an excellent financial health rating, but there are worries on the profitability. ALMS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALMS has reported negative net income.
ALMS had a negative operating cash flow in the past year.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -50.23%, ALMS is not doing good in the industry: 61.26% of the companies in the same industry are doing better.
ALMS has a Return On Equity of -63.71%. This is comparable to the rest of the industry: ALMS outperforms 47.12% of its industry peers.
Industry RankSector Rank
ROA -50.23%
ROE -63.71%
ROIC N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

ALMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ALMS has more shares outstanding than it did 1 year ago.
ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

ALMS has an Altman-Z score of 0.88. This is a bad value and indicates that ALMS is not financially healthy and even has some risk of bankruptcy.
ALMS has a Altman-Z score (0.88) which is comparable to the rest of the industry.
ALMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACCN/A
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 6.01 indicates that ALMS has no problem at all paying its short term obligations.
ALMS has a better Current ratio (6.01) than 68.59% of its industry peers.
ALMS has a Quick Ratio of 6.01. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.01, ALMS is doing good in the industry, outperforming 69.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.92% over the past year.
EPS 1Y (TTM)42.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.02% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.54%
EPS Next 2Y27.89%
EPS Next 3Y18.83%
EPS Next 5Y13.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALMS. In the last year negative earnings were reported.
Also next year ALMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

ALMS's earnings are expected to grow with 18.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.89%
EPS Next 3Y18.83%

More info and screens

0

5. Dividend

5.1 Amount

ALMS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ALUMIS INC

NASDAQ:ALMS (1/2/2026, 8:00:01 PM)

After market: 8.93 -0.03 (-0.28%)

8.955

-0.8 (-8.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-17 2026-03-17
Inst Owners46.85%
Inst Owner Change0%
Ins Owners0.82%
Ins Owner Change41.33%
Market Cap934.81M
Revenue(TTM)22.12M
Net Income(TTM)-245.15M
Analysts87.14
Price Target20.25 (126.13%)
Short Float %6.17%
Short Ratio3.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.49%
Min EPS beat(2)-19.57%
Max EPS beat(2)-13.42%
EPS beat(4)1
Avg EPS beat(4)7.68%
Min EPS beat(4)-20.07%
Max EPS beat(4)83.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.09%
Min Revenue beat(2)-28.51%
Max Revenue beat(2)30.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.51%
PT rev (3m)4.51%
EPS NQ rev (1m)-3.34%
EPS NQ rev (3m)-9.08%
EPS NY rev (1m)-4.72%
EPS NY rev (3m)-13.41%
Revenue NQ rev (1m)-16.67%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-2.12%
Revenue NY rev (3m)-2.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.26
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.8
EV/EBITDA N/A
EPS(TTM)-4.79
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-3.58
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS0.21
BVpS3.69
TBVpS3.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.23%
ROE -63.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.54%
Cap/Sales 4.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z 0.88
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)455.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.73%
EPS Next Y66.54%
EPS Next 2Y27.89%
EPS Next 3Y18.83%
EPS Next 5Y13.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.27%
EBIT Next 3Y-4.3%
EBIT Next 5YN/A
FCF growth 1Y-90.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.25%
OCF growth 3YN/A
OCF growth 5YN/A

ALUMIS INC / ALMS FAQ

Can you provide the ChartMill fundamental rating for ALUMIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ALMS.


What is the valuation status for ALMS stock?

ChartMill assigns a valuation rating of 0 / 10 to ALUMIS INC (ALMS). This can be considered as Overvalued.


What is the profitability of ALMS stock?

ALUMIS INC (ALMS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ALUMIS INC?

The Earnings per Share (EPS) of ALUMIS INC (ALMS) is expected to grow by 66.54% in the next year.